FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600596536> ?p ?o ?g. }

• W2600596536 endingPage "8015" @default.
• W2600596536 startingPage "8015" @default.
• W2600596536 abstract "8015 Background: Bisphosphonates (BPs) are recommended in pts with osteolytic lesions from MM. However, data on the long-term efficacy and safety of BPs beyond 2 y is somewhat limited. The MRC Myeloma IX study has already revealed significant overall survival (OS) and progression-free survival (PFS) benefits for zoledronic acid (ZOL) over clodronate (CLO) in MM pts (N = 1960) initiating chemotherapy (Morgan GJ, et al. Lancet. 2010). We now report the efficacy and safety of BP therapy with long-term follow-up. Methods: Newly diagnosed MM pts were randomized to ZOL (4 mg IV q 21-28 days) or CLO (1600 mg/day PO) plus antimyeloma therapy. BPs continued at least until disease progression. PFS and OS were estimated using Kaplan-Meier methodology. Hazard ratios (HRs) were calculated using stratified Cox models. Adverse events (AEs) were monitored continuously and analyzed using cumulative incidence functions. Results: At a median follow-up of 5.8 y in 1960 evaluable pts, ZOL improved PFS (HR = 0.88; P = .01) and OS (HR = 0.88; P = .03) vs CLO. Both BPs were generally well tolerated, and acute renal failure events were similar between groups (ZOL 5.2% vs CLO 5.8% at 2 y, with incidence plateaued thereafter). Overall incidence of confirmed osteonecrosis of the jaw (ONJ) has remained low (ZOL 3.7% vs CLO 0.5%; P < .0001). ONJ incidence was lower among pts receiving thalidomide-containing regimens (1.4%) vs no thalidomide (2.76%; P = .041). Events were generally low-grade, most occurred between 8 and 30 mo (median time to ONJ = 23.7 mo), and cumulative incidence plateaued at ~36 mo. Ten pts had data on ONJ recovery: complete recovery in 4 pts, improvement in 2 pts, no change in 3 pts in the ZOL group; and no change in 1 CLO pt. Dental surgery or trauma preceded ONJ in 6 ZOL pts. Conclusions: ZOL provided sustained PFS and OS improvements vs CLO during long-term therapy in the MRC Myeloma IX study. Overall incidence of AEs was similar between groups, with no notable changes during long-term therapy. ONJ incidence remained low during long-term (> 2.5 y) therapy and was reduced in pts receiving thalidomide (possibly because of anticytokine effects of this agent)." @default.
• W2600596536 created "2017-04-07" @default.
• W2600596536 creator A5003687947 @default.
• W2600596536 creator A5009505468 @default.
• W2600596536 creator A5012570136 @default.
• W2600596536 creator A5016246851 @default.
• W2600596536 creator A5016899907 @default.
• W2600596536 creator A5017165070 @default.
• W2600596536 creator A5017554622 @default.
• W2600596536 creator A5018664633 @default.
• W2600596536 creator A5034560778 @default.
• W2600596536 creator A5034702019 @default.
• W2600596536 creator A5038580329 @default.
• W2600596536 creator A5053100242 @default.
• W2600596536 creator A5060714042 @default.
• W2600596536 creator A5063301766 @default.
• W2600596536 creator A5065378097 @default.
• W2600596536 creator A5070032224 @default.
• W2600596536 creator A5081247376 @default.
• W2600596536 creator A5084971557 @default.
• W2600596536 creator A5085072463 @default.
• W2600596536 date "2012-05-20" @default.
• W2600596536 modified "2023-09-25" @default.
• W2600596536 title "Efficacy and side-effect profile of long-term bisphosphonate therapy in patients (pts) with multiple myeloma (MM): MRC myeloma IX study results." @default.
• W2600596536 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.8015" @default.
• W2600596536 hasPublicationYear "2012" @default.
• W2600596536 type Work @default.
• W2600596536 sameAs 2600596536 @default.
• W2600596536 citedByCount "1" @default.
• W2600596536 countsByYear W26005965362017 @default.
• W2600596536 crossrefType "journal-article" @default.
• W2600596536 hasAuthorship W2600596536A5003687947 @default.
• W2600596536 hasAuthorship W2600596536A5009505468 @default.
• W2600596536 hasAuthorship W2600596536A5012570136 @default.
• W2600596536 hasAuthorship W2600596536A5016246851 @default.
• W2600596536 hasAuthorship W2600596536A5016899907 @default.
• W2600596536 hasAuthorship W2600596536A5017165070 @default.
• W2600596536 hasAuthorship W2600596536A5017554622 @default.
• W2600596536 hasAuthorship W2600596536A5018664633 @default.
• W2600596536 hasAuthorship W2600596536A5034560778 @default.
• W2600596536 hasAuthorship W2600596536A5034702019 @default.
• W2600596536 hasAuthorship W2600596536A5038580329 @default.
• W2600596536 hasAuthorship W2600596536A5053100242 @default.
• W2600596536 hasAuthorship W2600596536A5060714042 @default.
• W2600596536 hasAuthorship W2600596536A5063301766 @default.
• W2600596536 hasAuthorship W2600596536A5065378097 @default.
• W2600596536 hasAuthorship W2600596536A5070032224 @default.
• W2600596536 hasAuthorship W2600596536A5081247376 @default.
• W2600596536 hasAuthorship W2600596536A5084971557 @default.
• W2600596536 hasAuthorship W2600596536A5085072463 @default.
• W2600596536 hasConcept C120665830 @default.
• W2600596536 hasConcept C121332964 @default.
• W2600596536 hasConcept C126322002 @default.
• W2600596536 hasConcept C126894567 @default.
• W2600596536 hasConcept C141071460 @default.
• W2600596536 hasConcept C143998085 @default.
• W2600596536 hasConcept C197934379 @default.
• W2600596536 hasConcept C207103383 @default.
• W2600596536 hasConcept C2776326535 @default.
• W2600596536 hasConcept C2776364478 @default.
• W2600596536 hasConcept C2776541429 @default.
• W2600596536 hasConcept C2776694085 @default.
• W2600596536 hasConcept C2777251235 @default.
• W2600596536 hasConcept C2777556957 @default.
• W2600596536 hasConcept C2779609412 @default.
• W2600596536 hasConcept C2780739268 @default.
• W2600596536 hasConcept C44249647 @default.
• W2600596536 hasConcept C61511704 @default.
• W2600596536 hasConcept C71924100 @default.
• W2600596536 hasConcept C72563966 @default.
• W2600596536 hasConcept C88879693 @default.
• W2600596536 hasConcept C90924648 @default.
• W2600596536 hasConceptScore W2600596536C120665830 @default.
• W2600596536 hasConceptScore W2600596536C121332964 @default.
• W2600596536 hasConceptScore W2600596536C126322002 @default.
• W2600596536 hasConceptScore W2600596536C126894567 @default.
• W2600596536 hasConceptScore W2600596536C141071460 @default.
• W2600596536 hasConceptScore W2600596536C143998085 @default.
• W2600596536 hasConceptScore W2600596536C197934379 @default.
• W2600596536 hasConceptScore W2600596536C207103383 @default.
• W2600596536 hasConceptScore W2600596536C2776326535 @default.
• W2600596536 hasConceptScore W2600596536C2776364478 @default.
• W2600596536 hasConceptScore W2600596536C2776541429 @default.
• W2600596536 hasConceptScore W2600596536C2776694085 @default.
• W2600596536 hasConceptScore W2600596536C2777251235 @default.
• W2600596536 hasConceptScore W2600596536C2777556957 @default.
• W2600596536 hasConceptScore W2600596536C2779609412 @default.
• W2600596536 hasConceptScore W2600596536C2780739268 @default.
• W2600596536 hasConceptScore W2600596536C44249647 @default.
• W2600596536 hasConceptScore W2600596536C61511704 @default.
• W2600596536 hasConceptScore W2600596536C71924100 @default.
• W2600596536 hasConceptScore W2600596536C72563966 @default.
• W2600596536 hasConceptScore W2600596536C88879693 @default.
• W2600596536 hasConceptScore W2600596536C90924648 @default.
• W2600596536 hasIssue "15_suppl" @default.
• W2600596536 hasLocation W26005965361 @default.
• W2600596536 hasOpenAccess W2600596536 @default.
• W2600596536 hasPrimaryLocation W26005965361 @default.

• next